Oruka Therapeutics, Inc.
A clinical-stage biotech developing longer-lasting antibody drugs for skin conditions like psoriasis, aiming for injections that may be needed only once or twice a year. Its lead candidates, ORKA-001 and ORKA-002, come from Paragon Therapeutics, a drug-discovery engine that also spawned other biotechs. The name blends Hebrew words for "skin" and "restoration," and the company went public in 2024 through a reverse merger with ARCA biopharma, trading as "ORKA."
Granted 333.3K
Granted 76.7K · Sold 3.5K
Granted 47.5K · Sold 24.2K
Granted 100.0K
Granted 81.5K · Sold 50.6K
Granted 62.3K · Sold 140.0K
Granted 32.5K · Sold 1.5K
Granted 34.8K · Sold 22.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC +4 co-filersDirector, 10% owner · 1 transaction | +26.2% | 3.71M | 333.3K | — | — |
| Klein Lawrence OttoChief Executive Officer, Director · 3 transactions | +8.6% | 925.6K | 76.7K | — | 3.5K |
| Sandler Laura LeeChief Operating Officer · 17 transactions | +10.9% | 236.4K | 47.5K | — | 24.2K |
| Edwards Larry ToddChief Commercial Officer · 1 transaction | — | 100.0K | 100.0K | — | — |
| Goncalves JoanaChief Medical Officer · 37 transactions | — | 39.0K | 81.5K | — | 50.6K |
| Dambkowski CarlDirector · 9 transactions | — | 38.7K | 62.3K | — | 140.0K |
| Quinlan Paul TGeneral Counsel · 3 transactions | — | 31.0K | 32.5K | — | 1.5K |
| Agarwal ArjunSenior Vice President, Finance · 16 transactions | — | 15.3K | 34.8K | — | 22.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -241.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.